Viread et al. are prodrugs (taken orally) used to treat and manage HIV and Hepatitis “C”. Viread is a billion-dollar blockbuster drug that is the backbone of the HAART treatment strategy. for HIV patients. Gilead developed two separate delivery systems, TDF and TAF, the former delivered the drug in a much higher dosage (even though Gliead had already developed the TAF delivery system, which delivered the drugs in much smaller dosage), which has resulted in a myriad of kidney issues including CKD, end stage renal disease, and fatal renal insufficiency as well as loss of bone density issues including Falconi Syndrome, Osteoporosis with pathological fracture and bone necrosis among others.

2/13/1019 – In the Superior Court of California, Judge Carolyn B Kuhl ruled that Plaintiffs’ allegations had merit and Gilead may be accountable for kidney and bone injuries that occurred in patients who were using their antiretroviral medications. Gilead will have to defend itself against Plaintiffs claiming that they failed to warn patients of the damaging side effects of TDF and actively misrepresenting TDF’s efficacy/risks, all the while knowing the safer alternative existed: tenofovir alafenamide (TAF).